Corrigendum to “A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma”

Qin S, Chan SL, Sukeepaisarnjaroen W, et al. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology. 2019;11.doi:10.1177/1758835919889001

Four instances of alpha fetoprotein (AFP) data have been updated in the Table 1 (Page 5) of the publication as follows:

The proportion of patients (n, %) with baseline AFP (40−⩽100 µg/l) in the column of Capmatinib dose 300 mg capsule (n = 8) changed from 1 (13) to 0; and from 4 (11) to 3 (8) in the column of All patients (n = 38). Similarly, patients with AFP (100−⩽1000 µ g/l) in the column of Capmatinib dose 300 mg capsule (n = 8) changed from 1 (13) to 2 (25); and 7 (18) to 8 (21) in the column of ‘All patients (n = 38).

This update to the baseline characteristics table does not affect the overall results and conclusion presented in this publication.